{"DataElement":{"publicId":"6306947","version":"1","preferredName":"Inotuzumab Ozogamicin Cycle Administered Count","preferredDefinition":"The number of inotuzumab ozogamicin cycles that were administered.","longName":"6337034v1.0:2018392v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"6337034","version":"1","preferredName":"Inotuzumab Ozogamicin Cycle Administered","preferredDefinition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora._An event or sequence of events that constitute a round or succession of observable phenomena, recurring usually at regular or approximately regular time intervals and in the same sequence._The act of having given something (e.g., a medication or test).","longName":"5724182v1.0:2763971v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"5724182","version":"1","preferredName":"Inotuzumab Ozogamicin","preferredDefinition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","longName":"C71542","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inotuzumab Ozogamicin","conceptCode":"C71542","definition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B52C4CB-AE3E-627C-E053-F662850A0E20","latestVersionIndicator":"Yes","beginDate":"2017-03-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-03-22","modifiedBy":"ONEDATA","dateModified":"2017-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2763971","version":"1","preferredName":"Cycle Administered","preferredDefinition":"An event or sequence of events that constitute round or succession of observable phenomena, recurring usually at regular or approximately regular time intervals and in the same sequence.:Given.","longName":"C25472:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cycle","conceptCode":"C25472","definition":"An event or sequence of events that constitute a round or succession of observable phenomena, recurring usually at regular or approximately regular time intervals and in the same sequence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"51989219-0D3C-38CC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-07-09","endDate":null,"createdBy":"STURGILLJ","dateCreated":"2008-07-09","modifiedBy":"ONEDATA","dateModified":"2008-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6F18A13C-3E4B-3EC3-E053-F662850A2C04","latestVersionIndicator":"Yes","beginDate":"2018-06-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-06-20","modifiedBy":"KUMMEROA","dateModified":"2018-07-25","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2018392","version":"1","preferredName":"Count","preferredDefinition":"The quantity of the specified item.","longName":"CT","context":"NCI Standards","contextVersion":"1","type":"Non-enumerated","dataType":"NUMBER","minLength":"1","maxLength":"2","minValue":null,"maxValue":null,"decimalPlace":"0","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008541","version":"1","preferredName":"Numbers","preferredDefinition":"the set of non-negative integers.","longName":"NUMS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B227CE66-2830-4A7B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2261845","version":"1","preferredName":"Count","preferredDefinition":"To determine the number or amount of something; the result of this activity.","longName":"C25463","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Count","conceptCode":"C25463","definition":"Determining the number or amount of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"FBB87F7A-646B-1AFC-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-13","modifiedBy":"ONEDATA","dateModified":"2005-07-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B3BF4389-4489-5F2C-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-09","endDate":null,"createdBy":"MWHITE","dateCreated":"2003-01-08","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/11/17 tt transferred context, added reg status and CSI per Round 5 finalization task.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"INOT_INO_ino_gt1_cyc_adm_cnt","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What was the number of inotuz","type":"Preferred Question Text","description":"What was the number of inotuzumab ozogamicin cycles that were administered?","url":null,"context":"NHLBI"},{"name":"Number of cycles:","type":"Alternate Question Text","description":"Number of cycles:","url":null,"context":"NHLBI"},{"name":"Number of cycles:","type":"Application Standard Question Text","description":"Number of cycles:","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6D6BC870-A9DA-5B92-E053-F662850ACB0B","latestVersionIndicator":"Yes","beginDate":"2018-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-05-30","modifiedBy":"KUMMEROA","dateModified":"2018-07-25","changeDescription":".; System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}